Net debt and capitalization -- $6.9 million in cash as of June 30, 2025, $6.6 million in debt facilities available as of June ...

AbCellera Reports Q2 2025 Business Results & Initiation of a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms ...

The summer heat may be the focus for many in Holland this August, but anticipation is growing for the more than $11 million ...

More than one million gallons of hazardous pollutants have been removed from the USS Yorktown as a years-long environmental ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Norris must not only sustain his form but also navigate the increasingly tense dynamics within the McLaren garage.

Q2 2025 Management View CEO Rodney Tyler Page highlighted that Cipher "delivered on all previously outlined plans at Black ...

Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025Fast Track ...

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, ...